Cell Line Development Market to exceed $7.5bn by 2024
Published Date: February 26, 2018 Author: Global Market Insights, Inc.
Cell Line Development Market size is set to exceed USD 7.5 billion by 2024; according to a new research report by Global Market Insights, Inc.
Growing cancer prevalence, increasing demand for vaccines and monoclonal antibodies, and mounting technological advancements coupled with innovations in biologics will stimulate the cell line development market growth over the forecast period. Growing favorable government initiatives for development of healthcare infrastructure, surge in vaccine production and increasing monoclonal antibodies demand will drive the market size.
Increasing disease prevalence in underdeveloped countries owing to adoption of western lifestyle, lack of physical exercise, consumption of harmful substances such as tobacco, alcohol, exposure to radiation and environmental pollutants will serve as a high impact rendering aspect for the business growth.
Browse key industry insights spread across 150 pages with 145 market data tables & 11 figures & charts from the report, “Cell Line Development Market By Product [Reagents & Media, Equipment (Incubator, Centrifuge, Bioreactor, Storage equipment, Microscope), Accessories & Consumables], By Source [Mammalian, Non-Mammalian (Insects, Amphibians)], By Cell Line [Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line], By Application [Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research] Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, France, Italy, Spain, Russia, China, India, Japan, South Korea, Australia, Brazil, Mexico, South Africa, Saudi Arabia), Technology Development, Competitive Landscape & Forecast, 2017 – 2024” in detail along with the table of contents:
Growing demand for biologics coupled with rising public awareness pertaining to cell therapy such as use of monoclonal antibodies in cancer treatment will propel the industry growth. Uncertain regulatory guidelines in developing countries for approval of biologics and diagnostics products will hamper the industry growth. Moreover, stem cell research related issues in developing economies will have negative impact on the business size.
Reagents and media market accounted for the highest revenue share and is anticipated to grow at a substantial rate in the coming years due to growing use of reagents and media for bio production, regenerative medicines, drug discovery, toxicity testing, research and tissue engineering. Non-mammalian source market should grow at a substantial rate over the forecast period pertaining to factors like growing use in production of vaccines for diseases such as rubella, mumps, measles in humans, and foot & mouth diseases in veterinary care will fuel the segment growth.
Primary cell line market will grow at considerable rate in the coming years. Rising use of primary cell lines as the most relevant mean for understanding core biological aspects of human and animal biology coupled introduction of novel technologies like 3D cell culture in primary cell line resulting in improved results and increasing usage will fuel the segment share. Tissue engineering will show noteworthy progress owing to increasing study the clinical relevance of the diseases and rising adoption rates of tissue engineering in patient treatment such as implantation of bladders. Bioreactor segment will grow at a considerable rate due to increasing use in large-scale manufacturing of biologics and to grow cells or tissues in cell culture.
U.S. is anticipated to grow significantly in the coming years owing to increasing adoption rates of cell culture techniques, high incidence of chronic diseases coupled with advancements in component technologies to improve the efficiency and speed of generating robust and highly productive cell line for large scale production of protein therapeutics.
Increase in demand for cell therapies in UK coupled with growing investments by manufacturers in biotechnology companies and rising funding by UK government for stem cell research in companies through technology strategy board will fuel regional revenue in the coming years.
Japan should witness lucrative growth over the forecast period owing to growing government investment in research institutes like RIKEN Center for Developmental Biology and Frontier Institute of Biomedical Research for regenerative medicine. Rising advancement in stem cell research, biotechnological innovations for development of cell line, advancement in protein expression will promote business growth.
Some of the companies operating in industry are GE Healthcare, Thermo Fisher Scientific, The European Collection of Cell Cultures, Lonza Group, Sigma-Aldrich, Samsung Biologic, Sartorius, Selexis, WuXi AppTec, GVK BIO, and Progenitor Cell Therapy.
New product launches, expansion of manufacturing facilities, mergers and acquisition, partnership and collaboration will mainly boost the business. Major industry participants will work to strengthen their position in the market by implementing these strategies.
Cell line development market research report include in-depth coverage of the industry with estimates & forecast in terms of revenue in USD billion from 2013 to 2024, for the following segments:
Cell Line Development Market by Product
- Reagents and media
- Storage equipment
- Accessories and consumables
Cell Line Development Market by Equipment
- Storage equipment
Cell Line Development Market by Source
- Mammalian cell line development
- Non-mammalian cell line development
Cell Line Development Market by Cell Line
- Recombinant cell lines
- Continuous cell lines
- Primary cell lines
Cell Line Development Market by Application
- Drug discovery
- Toxicity testing
- Tissue engineering
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia